| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/EXNR.1994.1019 |
| P698 | PubMed publication ID | 8313935 |
| P2093 | author name string | Huang D | |
| Gilbert JR | |||
| Alberts MJ | |||
| Corder EH | |||
| Strittmatter WJ | |||
| Goedert M | |||
| Jakes R | |||
| Weisgraber KH | |||
| Saunders AM | |||
| Dong LM | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 163-71; discussion 172-4 | |
| P577 | publication date | 1994-02-01 | |
| P1433 | published in | Experimental Neurology | Q5421127 |
| P1476 | title | Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype | |
| P478 | volume | 125 |
| Q64865286 | Q64865286 |
| Q58179024 | A cell biologist's view of new data in Alzheimer's disease research |
| Q33965127 | A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping or DNA sequencing. V. Analysis of case/control sampling designs: Alzheimer's disease and the apoprotein E locus |
| Q41056322 | A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins |
| Q51597644 | A randomized study of the influence of perfusion technique and pH management strategy in 316 patients undergoing coronary artery bypass surgery. II. Neurologic and cognitive outcomes. |
| Q48245913 | A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer's disease |
| Q40965861 | A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. |
| Q53201479 | APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. |
| Q35834037 | Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro |
| Q48311992 | Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death |
| Q43671271 | Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking |
| Q36998533 | Age, APOE and sex: Triad of risk of Alzheimer's disease |
| Q36311673 | Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent |
| Q41335909 | Alterations in apolipoprotein E expression during aging and neurodegeneration |
| Q93719553 | Aluminum and Alzheimer's disease |
| Q77787274 | Alzheimer's disease |
| Q40761339 | Alzheimer's disease: treatment research finds new targets |
| Q34161041 | Amyloidosis and Alzheimer's disease |
| Q48275574 | Analysis of a novel mechanism of neuronal toxicity produced by an apolipoprotein E-derived peptide. |
| Q41611073 | ApoE, Alzheimer's disease, and recovery from brain stress |
| Q24311818 | ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation |
| Q30539979 | ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice |
| Q36546467 | Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology |
| Q33933382 | Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease |
| Q72391030 | Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease |
| Q48217870 | Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease |
| Q24563061 | Apolipoprotein E and Alzheimer disease |
| Q41454720 | Apolipoprotein E and Alzheimer's disease: a review of recent studies |
| Q37060457 | Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. |
| Q40616184 | Apolipoprotein E and β‐amyloid (1–42) regulation of glycogen synthase kinase‐3β |
| Q36856567 | Apolipoprotein E e4 allele frequency in patients with multiple system atrophy |
| Q53221111 | Apolipoprotein E epsilon 4 allele distribution in Wernicke-Korsakoff syndrome with or without global intellectual deficits. |
| Q51988901 | Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. |
| Q48823947 | Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains |
| Q71879354 | Apolipoprotein E genotype in diverse neurodegenerative disorders |
| Q57319082 | Apolipoprotein E genotype in patients with alzheimer's disease: Implications for the risk of dementia among relatives |
| Q48750372 | Apolipoprotein E immunoreactivity in neurons and neurofibrillary degeneration of aged non-demented and Alzheimer's disease patients |
| Q72158566 | Apolipoprotein E in Creutzfeldt-Jakob disease |
| Q33921712 | Apolipoprotein E in the brain and its role in Alzheimer's disease |
| Q52826575 | Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain. |
| Q42462689 | Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease |
| Q53200531 | Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury |
| Q53215699 | Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. |
| Q37124428 | Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease |
| Q40999874 | Apolipoprotein E, synaptic plasticity and Alzheimer's disease |
| Q44591025 | Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease |
| Q40983052 | Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease |
| Q53229335 | Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. |
| Q35834165 | Apolipoprotein E4 and beta amyloid in senile plaques and cerebral blood vessels of aged rhesus monkeys. |
| Q48373276 | Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis |
| Q43559135 | Apolipoprotein E4 stimulates sulfation of glycosaminoglycans in neural cells |
| Q22248091 | Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease |
| Q34497951 | Apolipoprotein E: From lipid transport to neurobiology |
| Q33337322 | Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. |
| Q53312202 | Apolipoprotein E: a review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer's disease |
| Q28265290 | Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease |
| Q34621541 | Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases |
| Q33796541 | Apolipoprotein Ε ε4 frequency is increased among Chinese patients with frontotemporal dementia and Alzheimer's disease |
| Q48466960 | Apolipoprotein-E deficiency results in an altered stress responsiveness in addition to an impaired spatial memory in young mice |
| Q33532794 | Apolipoprotein-E forms dimers in human frontal cortex and hippocampus |
| Q48891767 | Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans |
| Q48655926 | Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease |
| Q48024701 | Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse |
| Q35098524 | Beta-amyloid and cholinergic neurons |
| Q41748143 | Biochemical diagnostic markers to detect early Alzheimer's disease |
| Q42008541 | Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology |
| Q41611021 | Brain microvascular changes in Alzheimer's disease and other dementias. |
| Q41144848 | Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture |
| Q35146030 | Causative and susceptibility genes for Alzheimer's disease: a review. |
| Q44301966 | Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients |
| Q92523174 | Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease |
| Q53218418 | Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. |
| Q42912092 | Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study |
| Q36740538 | Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions |
| Q53222443 | Cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. |
| Q40983058 | Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology |
| Q33714955 | Clinical rationale of genetic testing in dementia |
| Q40880097 | Current concepts in the pathogenesis of Alzheimer's disease |
| Q35107333 | Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype |
| Q46580059 | Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. |
| Q57972066 | Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3β identified by nano-electrospray mass spectrometry |
| Q48895375 | Diffuse Lewy body disease without amyloid plaques in a patient homozygous for apolipoprotein E allele epsilon 4: a case report |
| Q53327233 | Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. |
| Q53310562 | Distribution and expression of the alpha-tubulin mRNA in the hippocampus and the temporal cortex in Alzheimer's disease. |
| Q73719722 | Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts |
| Q34204320 | Experimental approaches and drugs in development for the treatment of dementia |
| Q41671941 | Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. |
| Q35809803 | Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice |
| Q74272670 | Expression of the apolipoprotein E gene does not affect motor recovery after sensorimotor cortex injury in the mouse |
| Q41664894 | Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. |
| Q34355252 | Gene identification in Alzheimer's disease |
| Q34053056 | Genetic connections between neurological disorders and cholesterol metabolism |
| Q41325962 | Genetics and head injury |
| Q71803407 | Head injury, amyloid β and Alzheimer's disease |
| Q36961152 | Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease |
| Q46804251 | High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. |
| Q32091544 | Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. |
| Q35764654 | Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. |
| Q48585195 | Induction of apolipoprotein E after traumatic brain injury in forensic autopsy cases |
| Q35834286 | Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. |
| Q21131068 | Interactions of metals and Apolipoprotein E in Alzheimer's disease |
| Q77761021 | Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus |
| Q24308731 | Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease |
| Q31108276 | Linking brain imaging and genomics in the study of Alzheimer's disease and aging |
| Q36318321 | Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism |
| Q30708127 | Magnetic resonance imaging in dementia. A study of brain white matter changes. |
| Q36885911 | Magnetic resonance spectroscopic changes in Alzheimer's disease. |
| Q36318674 | Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele |
| Q48656558 | Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural haematoma in rat. |
| Q44251907 | Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. |
| Q29041808 | Morphological, Biochemical, and Genetic Support for an Apolipoprotein E Effect on Microtubular Metabolisma |
| Q46386555 | Multiple pathways of apolipoprotein E signaling in primary neurons |
| Q53215966 | NIA/AIzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. |
| Q64948958 | Nanotechnological Strategies for Protein Delivery. |
| Q50594935 | Natural history of Alzheimer's disease: prognostic value of plateaux |
| Q34722021 | Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins |
| Q42485915 | Neurofibrillary tangles in Niemann-Pick disease type C. |
| Q28775941 | Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease |
| Q48468054 | Neuroprotective efficacy and mechanisms of novel pyrrolopyrimidine lipid peroxidation inhibitors in the gerbil forebrain ischemia model |
| Q35107338 | Neuropsychological deficits associated with Alzheimer's disease in the very-old: discrepancies in raw vs. standardized scores |
| Q73507862 | Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated |
| Q48635466 | Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes |
| Q48467216 | Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis |
| Q48682031 | Norepinephrine transmitter metabolite induces apoptosis in differentiated rat pheochromocytoma cells |
| Q33983175 | Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments |
| Q36797362 | Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease |
| Q36600561 | Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease. |
| Q36657656 | Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). |
| Q42528671 | Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele |
| Q51916319 | Polymorphism of apolipoproteine E in relation with Alzheimer and vascular dementia. |
| Q26740581 | Polymorphisms of apolipoprotein E and aneurysmal subarachnoid haemorrhage: A meta-analysis |
| Q28238269 | Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease |
| Q34498308 | Protein aggregates and dementia: is there a common toxicity? |
| Q34122676 | Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases |
| Q40242744 | Proteins in unexpected locations |
| Q41150751 | Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions |
| Q48015248 | Receptor binding of an apolipoprotein E-rich subfraction of high density lipoprotein to rat and human brain membranes |
| Q40567985 | Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis |
| Q24530141 | Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration |
| Q43715548 | Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures |
| Q33735332 | SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele |
| Q28569838 | Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat |
| Q48689500 | Significance of the variant and full-length forms of the very low density lipoprotein receptor in brain |
| Q48931984 | Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: impact of the epsilon4 allele on regional cerebral blood flow |
| Q44756500 | Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis |
| Q28771743 | Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth |
| Q49160372 | Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities |
| Q53213466 | Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. |
| Q41674335 | Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice |
| Q53227428 | Tacrine for Alzheimer's disease. Costs and benefits. |
| Q48390072 | Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease |
| Q41753165 | The 'research magnificent' in late life: psychiatric epidemiology and the primary health care of older adults |
| Q30152657 | The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease. |
| Q41235553 | The Alzheimer diseases |
| Q48375362 | The Dorothy Russell Memorial Lecture. The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms |
| Q40957058 | The Golgi apparatus and the pathogenesis of Alzheimer's disease |
| Q38722713 | The Therapeutic Potential of Cell Identity Reprogramming for the Treatment of Aging-Related Neurodegenerative Disorders |
| Q36897604 | The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease |
| Q48725967 | The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease |
| Q40940214 | The clinical epidemiology of Alzheimer's disease |
| Q47416476 | The complexity of the genotype-phenotype relationship and the limitations of using genetic "markers" at the individual level. |
| Q33841363 | The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease |
| Q46351285 | The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease |
| Q53216047 | The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. |
| Q34123651 | The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. |
| Q41308477 | The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization |
| Q41062817 | The molecular significance of amyloid beta-peptide for Alzheimer's disease |
| Q33971309 | The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection |
| Q53323913 | The use of apolipoprotein E genotyping as a diagnostic test in suspected Alzheimer's disease. |
| Q60368820 | Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease |
| Q33998658 | Very low density lipoprotein receptor in Alzheimer disease |
| Q80858318 | [ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk] |
Search more.